Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What next surprising earnings???
Where’s the link they sell it for 150K?????
There is still an rating off 2$ but for this moment too high. If it’s go s well in court mine astimation is between 0,70 and 1,50. There are not a lot outstanding shares. If they can raise money from investors or an good out look for the medicines!!!!!!!!!
Shoe that do we haven’t here
What is TFSA probably in Netherlands we have an other word for that tx
These companies are owned by immune pharmaceuticals
IMMUNE PHARMACEUTICALS INC.
Dochterondernemingen
EpiCept GmbH:
Cytovia Oncology Inc.
Maxim Pharmaceuticals Inc:
Immune Pharmaceuticals USA Corp.
Immune Pharmaceuticals Ltd.
Cytovia, Inc.:
https://m.marketscreener.com/quote/stock/IMMUNE-PHARMACEUTICALS-I-55018320/company/
He people are these share holders still valid
Next Earnings Date
Nov 23-2020
Source investing. Com
By some trade platforms you have too fill in an paper that you can find in the menu of the trading platform that you understand the risk of trading on the otc market fill that an send too your trading platform by fax or mail or post
When can Shares Held by All Insider being sold. is there any restriction????
Yes Thats why i was confused every time a read the news.
I have bad Eyes but had to see it better.
But still i believe IMNPQ is on th long run an good stock
Time will show
Sorry i have mistaken an other compagnie that i follow thats is immunty pharma and those is for ALS ipl344 drug
Als is bullous pemphigoid.
ALS. Amyotrofe laterale sclerose
Letterpenny
Immune Pharmaceuticals Inc strong buy?
I like penny stocks and hope for a breakthrough medicine for ALS.
It seems that this ophran drug (bertilimumab) had good resulds in the past. So i can read on the big internet it slows down ALS with 90%. If this proven in the futher its a good stock to buy. And can be taken over by big pharma. These are mine thougs.
best regards
Good for ABBVIE delay for Gilead Sciences & (galapagos) rheumatoid arthritis (RA)
Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.
The FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.
“We are disappointed in this outcome and will evaluate the points raised in the CRL for discussion with the FDA. We continue to believe in the benefit/risk profile of filgotinib in RA, which has been demonstrated in the FINCH Phase 3 clinical program,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.
“This CRL issued by the FDA is very disappointing given the robust and comprehensive data package provided. Despite today’s news, we continue to believe filgotinib has the potential to provide an effective, new treatment option for patients with rheumatoid arthritis, where there remains a significant unmet need,” said Dr. Walid Abi-Saab, Chief Medical Officer, Galapagos.
The MANTA and MANTA-RAy studies are fully recruited, with topline results anticipated in the first half of 2021. Filgotinib is currently under review by regulatory authorities around the world. Filgotinib recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending marketing authorization for filgotinib in the EU for the treatment of adults with moderate to severe RA who have responded inadequately or are intolerant of one or more disease-modifying anti-rheumatic drugs.
Will imunne pharmaceuticals investigate whether bertilimumab can be used against covid19. Because there are several xxxxxNab drugs currently being researched for this or would they do this in secret !!!!!! ??!?